Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL
Treatment and conditionWhere it standsTrials
Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1